These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17566038)

  • 1. Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.
    Grabellus F; Ebeling P; Worm K; Sheu SY; Antoch G; Frilling A; Schmid KW
    Gut; 2007 Jul; 56(7):1025-6. PubMed ID: 17566038
    [No Abstract]   [Full Text] [Related]  

  • 2. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
    Zheng S; Pan YL; Tao DY; Wang JL; Huang KE
    Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
    Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
    Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
    Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
    [No Abstract]   [Full Text] [Related]  

  • 5. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
    Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
    Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P
    Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621
    [No Abstract]   [Full Text] [Related]  

  • 7. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
    De Giorgi U
    J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583
    [No Abstract]   [Full Text] [Related]  

  • 8. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].
    Wang CM; Shi YQ; Fu H; Zhao GF; Zhou Y; Du CY; Ye YW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 May; 13(5):371-4. PubMed ID: 20499309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach.
    Harrison ML; Goldstein D
    Intern Med J; 2006 Jun; 36(6):367-77. PubMed ID: 16732863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour.
    Grimpen F; Yip D; McArthur G; Waring P; Goldstein D; Loughrey M; Beshay V; Chong G
    Lancet Oncol; 2005 Sep; 6(9):724-7. PubMed ID: 16129374
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].
    Zhao WY; Cao H; Zhang Y; Shen ZY; Wu ZY
    Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):857-62. PubMed ID: 19961019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation.
    Wakai T; Kanda T; Hirota S; Ohashi A; Shirai Y; Hatakeyama K
    Br J Cancer; 2004 Jun; 90(11):2059-61. PubMed ID: 15150562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K; Matsumoto T; Hirota S
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.
    Tamborini E; Gabanti E; Lagonigro MS; Negri T; Pilotti S; Pierotti MA; Pricl S
    Cancer Res; 2005 Feb; 65(3):1115; author reply 1115. PubMed ID: 15705916
    [No Abstract]   [Full Text] [Related]  

  • 17. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
    Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour.
    Abdulkader I; Cameselle-Teijeiro J; Forteza J
    Histopathology; 2005 Apr; 46(4):470-2. PubMed ID: 15810964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.